Anzeige
Mehr »
Login
Freitag, 19.04.2024 Börsentäglich über 12.000 News von 689 internationalen Medien
Goldaktie: Eine Erfolgsgeschichte, die seinesgleichen sucht, startet gerade richtig durch!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche
PR Newswire
151 Leser
Artikel bewerten:
(0)

Dr. Thomas Garthwaite to Chair Ondine Biomedical's Medical Advisory Board

VANCOUVER, British Columbia, March 1, 2018 /PRNewswire/ --Ondine Biomedical Inc. announces the appointment of Dr. Thomas Garthwaite as Chairman of the Medical Advisory Board.Dr. Garthwaite is currently the Vice President, Diabetes Care & Medical Director for Employee Health, and past Chief Operations Officer & Vice President, Clinical Services Group at Hospital Corporation of America (HCA) of Nashville, Tennessee.

Photo - https://mma.prnewswire.com/media/648952/Dr_Thomas_Garthwaite.jpg

Prior to joining Hospital Corporation of America, Dr Garthwaite served in a number of other healthcare institutions including Catholic Health East (EVP & CMO), the Los Angeles County Department of Health Services (Director & Chief Medical Officer) and the Department of Veteran Affairs (Under Secretary for Health). He also served as Associate Professor & Associate Dean, Medical College of Wisconsin.

"We are very pleased to welcome Dr. Garthwaite to our Medical Advisory Board," stated Carolyn Cross CEO of Ondine Biomedical Inc., "He brings with him a wealth of experience that will help us develop our Photodisinfection based technologies to improve patient safety and infection control. He has a long history working with infection control and supporting innovation that advances patient outcomes."

About Ondine Biomedical Inc.:

Ondine Biomedical Inc. is a Vancouver based medical device company dedicated to the development of non-antibiotic anti-infective therapies for a broad spectrum of bacterial, viral and fungal infections. Ondine's platform technology is called Photodisinfection, a patented light activated technology that provides rapid antimicrobial efficacy without encouraging antibiotic resistance. Ondine's lead product is the MRSAid' nasal decolonization system which is used to decolonize the nose of all types of pathogens including methicillin-resistant Staphylococcus aureus (MRSA). Several next-generation products in the hospital-associated infection market are currently under development.

Contact Ondine Biomedical, Inc., Angelika Vance, Director - Corporate Development, avance@ondinebio.com


Großer Insider-Report 2024 von Dr. Dennis Riedl
Wenn Insider handeln, sollten Sie aufmerksam werden. In diesem kostenlosen Report erfahren Sie, welche Aktien Sie im Moment im Blick behalten und von welchen Sie lieber die Finger lassen sollten.
Hier klicken
© 2018 PR Newswire
Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.